These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
3. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392 [TBL] [Abstract][Full Text] [Related]
4. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers. Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154 [TBL] [Abstract][Full Text] [Related]
6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145 [TBL] [Abstract][Full Text] [Related]
7. Update on genetic predisposition to breast cancer. Ahmed M; Lalloo F; Evans DG Expert Rev Anticancer Ther; 2009 Aug; 9(8):1103-13. PubMed ID: 19671030 [TBL] [Abstract][Full Text] [Related]
8. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12. Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690 [TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Antoniou AC; Durocher F; Smith P; Simard J; Easton DF; Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652 [TBL] [Abstract][Full Text] [Related]
10. [Clinical and molecular diagnosis of inherited breast-ovarian cancer]. Chompret A J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301 [TBL] [Abstract][Full Text] [Related]
11. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399 [TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786 [TBL] [Abstract][Full Text] [Related]
13. [Implications of genetic risk factors in breast cancer: culprit genes and associated malignancies]. Stoppa-Lyonnet D; Buecher B; Houdayer C; de Pauw A; Gauthier-Villars M; de la Rochefordière A; This P; Asselain B; Andrieu N Bull Acad Natl Med; 2009 Dec; 193(9):2063-83; discussion 2084-5. PubMed ID: 20690207 [TBL] [Abstract][Full Text] [Related]
14. Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Bonadona V; Sinilnikova OM; Chopin S; Antoniou AC; Mignotte H; Mathevet P; Brémond A; Martin A; Bobin JY; Romestaing P; Raudrant D; Rudigoz RC; Léoné M; Chauvin F; Easton DF; Lenoir GM; Lasset C Genes Chromosomes Cancer; 2005 Aug; 43(4):404-13. PubMed ID: 15887246 [TBL] [Abstract][Full Text] [Related]
15. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856 [TBL] [Abstract][Full Text] [Related]
16. Breast cancer genetics: what we know and what we need. Nathanson KL; Wooster R; Weber BL Nat Med; 2001 May; 7(5):552-6. PubMed ID: 11329055 [TBL] [Abstract][Full Text] [Related]
17. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019 [TBL] [Abstract][Full Text] [Related]
18. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254 [TBL] [Abstract][Full Text] [Related]
19. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514 [TBL] [Abstract][Full Text] [Related]
20. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. King MC; Marks JH; Mandell JB; Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]